Traws Pharma Inc
TRAW
$0.35
Closing
▲3.25%
1D
▼-53.10%
YTD
TRAW
BBG001T921M7
Market cap
$8.85M
52 week high
$1.07
52 week low
$0.33
Volume
4,072
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $6.99/month
Market cap
$8.85M
Analysts' Rating
STRONG BUY
Price Target (Mean)
6.50
Total Analysts
0
P/E
Operating Margin
-216400.00%
Beta
1.41
Revenue Growth
0.00%
52 week high
$1.07
52 week low
$0.33
Div. Yield
%
EPS Growth
0.00
Company Profile
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).
